References
- Hofbauer L. C., Heufelder A. E. Role of receptor activator of nuclear factor‐κB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243–53
- Khosla S. Minireview. The OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050–5
- Klein D. A., Walsh B. T. Eating disorders: clinical features and pathophysiology. Physiol Behav 2004; 81: 359–74
- Rodrigez‐Cano T., Beato‐Fernández L., Belmonte‐Llario A. New contributions to the prevalence of eating disorders in Spanish adolescents: detection of false negatives. Eur Psychiat 2005; 20: 173–8
- Muñoz M. T., Argente J. Anorexia nervosa in female adolescents: endocrine and bone mineral density disturbances. Eur J Endocrinol 2002; 147: 275–86
- Argente J., Barrios V., Chowen J. A., Sinha M. K., Considine R. V. Leptin plasma levels in healthy Spanish children and adolescents, children with obesity, and adolescents with anorexia nervosa and bulimia nervosa. J Pediatr 1997; 131: 833–8
- Misra M., Soyka L. A., Miller K. K., Herzog D. B., Grinspoon S., Dechen D., et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2003; 88: 3816–22
- Hernández M., Sánchez E., Sobradillo B. Curvas y tablas de crecimiento [Growing graphics and tables]. J Argente, A Carrascosa, R Gracia, F Rodríguez. Doyma, Barcelona 2000; 1333–51, Tratado de endocrinología pediátrica y de la adolescencia [Pediatric endocrinology and adolescence book]
- Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 2004; 4: 295–300
- Kahl K. G., Rudolf S., Dibbelt L., Stoeckelhuber B. M., Gehl H. B., Hohagen F., et al. Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. Osteoporos Int 2005; 16: 424–9
- Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518–27
- Hofbauer L. C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490–5
- Rogers A., Saleh G., Hannon R. A., Greenfield D., Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 4470–8
- Naylor K. E., Rogers A., Fraser R. B., Hall V., Eastell R., Blumsohn A. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 2003; 88: 5361–5
- Calero J. A., Muñoz M. T., Argente J., Traba M. L., Méndez‐Dávila C., García Moreno C., et al. A variation in bone alkaline phosphatase levels that correlates positively with bone loss and normal levels of aminoterminal propeptide of collagen I in girls with anorexia nervosa. Clin Chim Acta 1999; 285: 121–9
- Burguera B., Hofbauer L. C., Thomas T., Gori F., Evans G. L., Khosla S., et al. Leptin reduces ovariectomy‐induced bone loss in rats. Endocrinology 2001; 142: 3546–53
- Thomas T., Gori F., Khosla S., Jensen M. D., Burguera B., Riggs B. L. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140: 1630–8
- Thomas T., Burguera B., Melton L. J 3rd., Atkinson E. J., O'Fallon W. M., Riggs B. L., et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001; 29: 114–20
- Tamasi J. A., Arey B. J., Bertolini D. R., Feyen J. H. M. Characterization of bone structure in leptin receptor‐deficient Zucker (fa/fa) rats. J Bone Miner Res 2003; 18: 1605–11